Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;9(4):527-32.
doi: 10.1177/1756283X16636781. Epub 2016 Mar 15.

Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease

Affiliations
Review

Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease

Sandro Ardizzone et al. Therap Adv Gastroenterol. 2016 Jul.

Abstract

In Crohn's disease (CD), the tissue-damaging inflammation is sustained by defects of counter-regulatory mechanisms, which normally inhibit immune-inflammatory signals and promote repair of mucosal injury. In particular, in inflamed gut of CD patients there are elevated levels of Smad7, an intracellular protein that inhibits the function of transforming growth factor (TGF)-β1. Knockdown of Smad7 with a specific antisense oligonucleotide, named mongersen, restores TGF-β1 activity thus leading to suppression of inflammatory pathways and resolution of colitis in mice. Consistently, oral administration of mongersen to patients with active CD induces clinical remission. In this article, we review the available data supporting the pathogenic role of Smad7 in CD and discuss the results of recent phase I and II trials assessing the efficacy and safety of mongersen in CD patients.

Keywords: IBD; Smad7; TGF-β; colitis; mucosal immunity.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: G. Monteleone has filed a patent related to the treatment of inflammatory bowel diseases with Smad7 antisense oligonucleotides. The remaining authors have no conflict of interest to disclose.

Figures

Figure 1.
Figure 1.
Schematic illustration showing the TGF-β1-associated Smad pathway in normal (a) and inflamed (b) intestine. Physiologically active TGF-β1 binds to the TGF-β receptor subunit II (RII) and promotes phosphorylation (p) and activation of TGF-β receptor subunit I (RI), thus leading to phosphorylation of Smad2 and Smad3. Once phosphorylated, Smad2 and Smad3 interact with Smad4 and the complex translocates to the nucleus, where it controls the transcriptional activity of multiple genes, including those encoding for inflammatory molecules (a). In the gut of patients with inflammatory bowel diseases (b) there is a defective TGF-β1-associated Smad pathway, because cells express elevated levels of Smad7, an intracellular protein whose expression is regulated by molecules that enhance its acetylation status (i.e. p300). Smad7 binds to TGF-βRI and prevents phosphorylation of Smad2 and Smad3, with the downstream effect of suppressing TGF-β1-driven counter-regulatory properties, thus amplifying inflammatory gene expression. TGF, transforming growth factor.

Similar articles

Cited by

References

    1. Abdollah S., Macías-Silva M., Tsukazaki T., Hayashi H., Attisano L., Wrana J. (1997) TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 272: 27678–27685. - PubMed
    1. Babyatsky M., Rossiter G., Podolsky D. (1996) Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975–984. - PubMed
    1. Boirivant M., Fuss I., Chu A., Strober W. (1998) Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 188: 1929–1939. - PMC - PubMed
    1. Boirivant M., Pallone F., Di Giacinto C., Fina D., Monteleone I., Marinaro M., et al. (2006) Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 131: 1786–1798. - PubMed
    1. Border W., Noble N. (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 33: 1286–1292. - PubMed